Literature DB >> 19233670

Mitral valve surgery for functional mitral regurgitation: prognostic role of tricuspid regurgitation.

Michele Di Mauro1, Antonio Bivona, Angela L Iacò, Marco Contini, Massimo Gagliardi, Egidio Varone, Sabina Gallina, Antonio M Calafiore.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the impact of untreated moderate-or-more functional tricuspid regurgitation (FTR) on mid-term outcome of patients with functional mitral regurgitation (FMR) undergoing mitral valve surgery (MVS).
METHODS: From January 1988 to April 2003, 165 patients having FMR underwent MVS with untreated FTR. Patients with organic mitral or tricuspid valve disease were excluded. The entire population was divided into two groups, group A: 102 patients (FTR 0/1+), group B: 63 patients (FTR 2+/3+). No statistical difference was found between two groups concerning preoperative and operative variables. MV was repaired in 137 and replaced in 28 cases; the impact of untreated moderate-or-more FTR was estimated by Cox analysis.
RESULTS: Thirty-day mortality was 6.7 (5.9% group A vs 7.9% group B, p=0.607). Five-year actuarial survival was 73.5% (66.6-80.4%); 88.2% (83.0-93.4%) group A versus 46.0% (33.7-58.3%) group B, p<0.001; the possibility to be alive in NYHA class I-II was 65.8% (58.4-73.2%); 78.4% (72.3-84.5%) group A versus 41.2% (29.1-53.3%) group B, p<0.001. Cox analysis confirmed the impact of untreated moderate-or-more FTR on 5-year survival (HR=3.1, 95% CI=1.8-5.1, p<0.001) and possibility to be alive in NYHA class I-II (HR=3.0, 95% CI=1.8-4.9, p<0.001). After a median interval time of 28 months (IQR=11-60), TR grade was echocardiographically assessed in 122 (79.2%) of 154 patients surviving the first month. In group A (87 patients), TR grade decreased significantly from 0.7+/-0.5 to 0.3+/-0.5 (p<0.001) in the early postoperative period. Then, it increased again to 0.6+/-0.7 at follow-up (p<0.001); no difference was found between preoperative and follow-up time (p=ns). In group B (35 cases), TR grade decreased significantly from 2.2+/-0.4 to 1.3+/-0.7 in the early postoperative period (p<0.001), but then increased again to 2.2+/-0.9 (p<0.001 vs postoperative value; p=0.838 vs preoperative value). Cox analysis confirmed that the progression of TR grade at follow-up is a risk factor for lower survival and possibility to be alive in NYHA class I-II.
CONCLUSIONS: Patients with untreated moderate-or-more FTR had survival and survival in NYHA class I-II lower than patients with untreated less-than-moderate FTR at 5-year follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 19233670     DOI: 10.1016/j.ejcts.2008.12.040

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  16 in total

Review 1.  Tricuspid regurgitation: pathophysiology and management.

Authors:  Rashmi Thapa; Buddhadeb Dawn; Jayant Nath
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

2.  A detailed mechanical and microstructural analysis of ovine tricuspid valve leaflets.

Authors:  William D Meador; Mrudang Mathur; Gabriella P Sugerman; Tomasz Jazwiec; Marcin Malinowski; Matthew R Bersi; Tomasz A Timek; Manuel K Rausch
Journal:  Acta Biomater       Date:  2019-11-22       Impact factor: 8.947

3.  New insight into tricuspid valve anatomy from 100 hearts to reappraise annuloplasty methodology.

Authors:  Yoshito Sakon; Takashi Murakami; Hiromichi Fujii; Yosuke Takahashi; Akimasa Morisaki; Kokoro Yamane; Masahiko Ohsawa; Ayumi Shintani; Toshiko Seki; Toshihiko Shibata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-02-25

4.  Long-term echocardiographic follow-up of untreated 2+ functional tricuspid regurgitation in patients undergoing mitral valve surgery.

Authors:  Kunio Kusajima; Tomoyuki Fujita; Hiroki Hata; Yusuke Shimahara; Sayaka Miura; Junjiro Kobayashi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-03-18

5.  Effect of tricuspid regurgitation and the right heart on survival after transcatheter aortic valve replacement: insights from the Placement of Aortic Transcatheter Valves II inoperable cohort.

Authors:  Brian R Lindman; Hersh S Maniar; Wael A Jaber; Stamatios Lerakis; Michael J Mack; Rakesh M Suri; Vinod H Thourani; Vasilis Babaliaros; Dean J Kereiakes; Brian Whisenant; D Craig Miller; E Murat Tuzcu; Lars G Svensson; Ke Xu; Darshan Doshi; Martin B Leon; Alan Zajarias
Journal:  Circ Cardiovasc Interv       Date:  2015-04       Impact factor: 6.546

6.  Current transcatheter devices to treat functional tricuspid regurgitation with discussion of issues relevant to clinical trial design.

Authors:  Rebecca T Hahn
Journal:  Ann Cardiothorac Surg       Date:  2017-05

7.  Impact of baseline tricuspid regurgitation on long-term clinical outcomes and survival after interventional edge-to-edge repair for mitral regurgitation.

Authors:  Robert Schueler; Can Öztürk; Jan-Malte Sinning; Nikos Werner; Armin Welz; Christoph Hammerstingl; Georg Nickenig
Journal:  Clin Res Cardiol       Date:  2016-12-21       Impact factor: 5.460

8.  Multi-parametric quantification of tricuspid regurgitation using cardiovascular magnetic resonance: A comparison to echocardiography.

Authors:  Diego Medvedofsky; Javier León Jiménez; Karima Addetia; Amita Singh; Roberto M Lang; Victor Mor-Avi; Amit R Patel
Journal:  Eur J Radiol       Date:  2016-11-23       Impact factor: 3.528

9.  Severity of tricuspid regurgitation is associated with long-term mortality.

Authors:  Brian J Kelly; Jamahal Maeng Ho Luxford; Carolyn Goldberg Butler; Chuan-Chin Huang; Kerry Wilusz; Julius I Ejiofor; James D Rawn; John A Fox; Stanton K Shernan; Jochen Daniel Muehlschlegel
Journal:  J Thorac Cardiovasc Surg       Date:  2017-11-08       Impact factor: 5.209

10.  Intraoperative method based on tricuspid annular circumference in patients with mild or no tricuspid regurgitation during left-sided cardiac valve surgery for the prophylactic tricuspid annuloplasty.

Authors:  Mohammad Sharif Popal; Jin-Tao Fu; Qiu-Ming Hu; Tian-Ge Luo; Shuai Zheng; Xu Meng
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.